Literature DB >> 11121992

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.

P Iversen1, I Melezinek, A Schmidt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11121992     DOI： 10.1046/j.1464-410x.2001.00988.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  9 in total

Review 1.  What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?

Authors:  Malcolm Mason
Journal:  J Cancer Res Clin Oncol       Date:  2006-08       Impact factor: 4.553

2.  The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.

Authors:  William A See; Chris J Tyrrell
Journal:  J Cancer Res Clin Oncol       Date:  2006-08       Impact factor: 4.553

Review 3.  Bicalutamide: in early-stage prostate cancer.

Authors:  Christopher I Carswell; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Antiandrogen treatments in locally advanced prostate cancer: are they all the same?

Authors:  David Gillatt
Journal:  J Cancer Res Clin Oncol       Date:  2006-08       Impact factor: 4.553

5.  Findings of Gynecomastia That Developed in Follow-up Secondary to Bicalutamide Treatment on Bone Scan.

Authors:  Kemal Ünal; Nahide Gökçora
Journal:  Mol Imaging Radionucl Ther       Date:  2020-04-29

6.  Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer.

Authors:  Nicola J Nasser
Journal:  Cancers (Basel)       Date:  2022-04-13       Impact factor: 6.575

Review 7.  Tamoxifen for the management of breast events induced by non-steroidal antiandrogens in patients with prostate cancer: a systematic review.

Authors:  Frank Kunath; Bastian Keck; Gerd Antes; Bernd Wullich; Joerg J Meerpohl
Journal:  BMC Med       Date:  2012-08-28       Impact factor: 8.775

Review 8.  Six-month depot formulation of leuprorelin acetate in the treatment of prostate cancer.

Authors:  Rajni Sethi; Nicholas Sanfilippo
Journal:  Clin Interv Aging       Date:  2009-06-09       Impact factor: 4.458

9.  Leuprorelin depot injection: patient considerations in the management of prostatic cancer.

Authors:  Zinelabidine Abouelfadel; E David Crawford
Journal:  Ther Clin Risk Manag       Date:  2008-04       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.